# Quantum Pharma PLC Pre-close trading update – on plan

- Link: https://www.directorstalkinterviews.com/quantum-pharma-plc-pre-close-trading-update-plan/412722806
- Published: 2017-02-01T07:17:32+00:00
- Author: Giles Arbor

**Quantum Pharma plc** (LON:QP), the service-led niche pharmaceutical manufacturer,
developer and supplier to the health and care sectors, has released a pre-close 
trading update this morning. Zeus Capital said: The Board has indicated that adjusted
EBITDA for the financial year (to Jan 31st) is expected to be in-line with market
expectations (we forecast £10.1m) and that net debt will be approximately £13.5m
following the successful fund raising in November last year. Following management’s
strategic review of the Group it has re-directed efforts within the key divisions
to focus and strengthen operations. Trading at NuPharm has ceased as planned and
the unlicensed-to-licensed (UL2L) portfolio has been prioritized enhancing the opportunity
to be first-to-market. We are confident that the changes made have set the company
on the right path for the longer term. Based on our unchanged forecasts Quantum 
is valued at 9.4x EV/EBITDA for FY2017 (year just completed) falling to 8.2x for
the coming year.

As highlighted in the company’s update and earlier announcements, in addition to
the cessation of trading at the loss-making NuPharm, key changes have been made 
to the company in the past few months including:

* UL2L pipeline– the Niche Pharmaceuticals division has been operationally streamlined
such that all products in the current UL2L pipeline are under ‘active development’
with Lamda controlling the processes such as product formulation and bioavailability
as well as preparation and submission of regulatory filings. The pipeline has been
prioritised to enhance the commercial potential for the company by focusing on products
where there is a greater chance of being first-to-market.

* Board and financing – following the successful equity fund raising of £15m (gross)
in November 2016, the company has reduced its net debt to ensure the Group is well-
financed and strengthened the Board with new appointments (Chris Rigg – CEO; Gerard
Murray – CFO; Ian Johnson – Chairman; and experienced Non-Execs, Dr John Brown and
Christopher Mills).

Management has indicated that the reported final results will contain some significant
one-off, mostly non-cash, exceptional items the most important of which relates 
to NuPharm and associated write down of the Balance Sheet value of the investment.

As mentioned in October with the Interim results, the group experienced slower-than-
expected sales of some of its generic and generic-plus products. Quantum has begun
work to broaden its network of UK and international commercial relationships with
a view to improving market penetration for selected generic products where it sees
value in deals with partners that have greater sales and marketing expertise and
presence in the generic pharma markets.

Comment: We are encouraged that management is focusing on the Group’s valuable core
operations and delivering on its new strategic directions, particularly in areas
where Group performance has been challenged due to issues within the divisions. 
The Group is clearly on a much more solid financial and operational footing for 
the coming years. The company’s full year results will be reported on Wednesday,
May 3rd.

>  **Chris Rigg, CEO of Quantum Pharma PLC, said:** “The Group has made solid progress
> in simplifying and focusing on its core value opportunities. Prioritising the 
> development of the UL2L products in our pipeline has given us a better opportunity
> to be first to market and drive value from the portfolio. We have taken decisive
> action to close a loss-making operation and have put the Group on a stronger financial
> footing going forward. I am pleased to report that we are executing in line with
> our plans.”

Share on:
